Senti Biosciences is trading at $0.22, down 5.36%, with no fresh company-specific announcement or reliable report identified to explain the October 21 decline.
- The latest release listed on the company’s investor page is dated July 15.
- Shareholders approved a merger and possible reverse split on October 15; available information does not establish either caused the decline.
- Biotech-sector strength was reported, and no volume figure is available in the supplied live-price context.